We cover a range of clinical trial studies in different therapy areas and conditions, which do change periodically. Register your interest with Bioluminux, or read about our trials below to find out more. If you have any queries about specific research, please get in touch with us directly or visit our FAQs section for more details.
Register Interest
A clinical research study is now enrolling adults diagnosed with bipolar disorder who are currently experiencing episodes of depression. The study is evaluating whether an investigational treatment, given alongside usual care, may help improve symptoms of depression.
Those who qualify may receive:
Study treatment or placebo (inactive substance) in addition to current care
Ongoing monitoring and support from a dedicated study team
Reimbursement for time, travel, and study-related expenses
An opportunity to contribute to the future of bipolar disorder research
Do you have high blood pressure that remains uncontrolled despite taking regular medication? You may be able to join a clinical research study testing an investigational treatment
This study is designed for adults with uncontrolled hypertension who also have established cardiovascular disease (such as heart attack, stroke, or artery disease) or are at high risk of developing cardiovascular disease. The trial will evaluate whether a test medication, given once every 6 months in addition to current standard treatments, can help reduce the risk of major cardiovascular events such as heart attack, stroke, or hospitalization for heart failure
Those who qualify may receive:
Investigational treatment or placebo in addition to current medication
Regular blood pressure checks, heart health monitoring, and safety assessments
Care and support from a dedicated research team
Reimbursement for time and travel expenses
An opportunity to contribute to new research in high blood pressure and heart health
Are you 18 years or older?
Are you diagnosed with IgAN from a kidney biopsy, or are you willing to have a biopsy if needed?
This study will evaluate a study drug versus placebo given every 4 weeks to people with immunoglobulin A nephropathy (IgAN) to learn if it impacts the disease.
Join the RAINIER Study, an IgAN autoimmune disease clinical trial, currently enrolling.
Study Participants may receive:
Study drug or placebo (which contains no active ingredients)
Support from a specialized study team
Reimbursement for travel and study participation expenses
An opportunity to help advance rare autoimmune disease research
Chronic kidney disease is a common condition, but many people who are living with it don't know that they have it.People in the Black Community are at a higher risk of developing APOL-1 mediate kidney disease.
If you have chronic kidney disease or kidney problems run in your family and are of African descent, you may be able to participate in a clinical research study for APOL1-mediated kidney disease.
Living with vitiligo?
Would you be interested in participating in a vitiligo research study to test an investigational drug called afamelanotide?
Eligible patients will receive ultraviolet light therapy, either alone or in combination with afamelanotide.
You may be eligible to participate if you:
Have vitiligo on your face and body
Have a medium to dark skin type
Are able to attend up to 14 clinic visits over 12 months
Are aged 12+ Eligible patients will be reimbursed for their time.
Living with type 2 diabetes and obesity can feel overwhelming, but you're not alone. Join our clinical trial and help advance treatment options for both conditions. This study is testing an investigational GLP-1 treatment aimed at improving outcomes for individuals struggling with weight gain and type 2 diabetes.
Key Requirements:
Age: 18-75
Condition: Struggling with obesity and type 2 diabetes.
Medications: Not currently on insulin or other GLP-1 products (you may be on other medications for type 2 diabetes).
BMI: Between 27 kg/m² and 50 kg/m².
Exclusion: Not eligible if you have type 1 diabetes or if you are currently taking insulin or other GLP-1 products.
You'll be compensated for your time
The study treatment
will last for 28 weeks, with follow-up visits, bringing the total duration to 43
weeks.
What's being tested?
An investigational GLP-1 treatment
for obesity and type 2 diabetes.
Who would not qualify?
If you are currently taking
insulin or other GLP-1 products.
Interested? Submit your details and one of our staff members will be in touch with you
Struggling with the pain and discomfort of acute gout flares? We're seeking participants for a clinical trial that could offer a new approach to managing this painful condition. If you've experienced multiple gout flare-ups in the past year, this is your chance to contribute to research focused on improving treatment options.
Key Inclusion Criteria:
Age: 18-70 years old (inclusive), male or female.
BMI: 18-40 kg/m² (inclusive).
Condition: Must have an established diagnosis of gout based on the American College of Rheumatology (ACR) criteria.
Experience: Have had 2 or more gout flares within the last 12 months.
What's in it for You:
Test a new investigational treatment designed to reduce the frequency and severity of acute gout flares.
Receive compensation for your time and involvement.
Help us make a difference for others living with gout.
Do migraines show up around your period? You're not alone; we're working on a better way to manage them.
We're inviting women to take part in a clinical research study looking at a new investigational medication for the intermittent prevention of menstrual migraine...
Interested in Taking Part? Start by Answering a Few Quick Questions
Living with COPD? Take a Breath—We're Researching New Treatment Options
Do flare-ups make it harder to catch your breath or stay active? You're not alone—and a new clinical research study is looking at a potential treatment that could help people living with moderate to severe COPD breathe easier and reduce flare-ups. This study is designed to evaluate the safety and effectiveness of an investigational medication for people whose COPD symptoms remain challenging despite being on inhalers and current therapies.
What's this study about?
People with Chronic Obstructive Pulmonary Disease (COPD) often face worsening symptoms, especially when flare-ups (exacerbations) happen frequently. These flare-ups can speed up the decline in lung function, leading to even more difficulty in breathing. This study focuses on people who experience frequent flare-ups, even while using standard inhalers. We're studying a treatment that targets inflammation—one of the underlying causes of flare-ups—to see if it can help improve breathing, reduce symptoms, and slow disease progression.
Study Duration:
The treatment period may last up to 108 weeks, with regular check-ins along the way.
Compensation:
If you qualify and participate, you'll be compensated for your time and travel.
You May Be Eligible If You:
Are between 40 and 84 years old
Have had a COPD diagnosis for over a year
Have a BMI over 16 kg/m²
Are a current or former smoker with at least 10 pack-years of smoking history
Have had:
2 or more moderate flare-ups OR 1 or more severe flare-up in the last year
Are currently on stable triple therapy (ICS + LABA + LAMA) or double therapy (LABA + LAMA if ICS isn't suitable)
Had at least one flare-up while on your regular inhaler medication
Living with severe asthma that isn't well controlled, even with your current medications? You may be able to take part in a clinical research study evaluating an investigational oral treatment for People with severe asthma.
The study will compare the investigational treatment with placebo (inactive tablet) over a 12 -month period to understand its effects on asthma symptoms, lung function, and quality of life.
Those who qualify may receive:
Investigational treatment or placebo
Regular check-ups, breathing tests, and safety monitoring
Care from a dedicated research team
Reimbursement for time and travel expenses
An opportunity to help advance asthma research
We're looking for individuals with asthma. If you are interested, simply register your details
Depression Research Study (Major Depressive Disorder)
Are you 18 to 65 years old?
Do you have Major Depressive Disorder (MDD)?
Have you experienced an inadequate response to your current antidepressant (SSRI or SNRI)?
A clinical research study is now enrolling adults diagnosed with MDD to evaluate whether an investigational medication, taken alongside a standard antidepressant, may improve symptoms of depression.
Participants will continue taking their existing antidepressant and receive either the study medication or a placebo (contains no active ingredients).Those who qualify may receive:
Study medication or placebo in addition to your current treatment
Care and monitoring from a dedicated study team
Reimbursement for time, travel, and study-related expenses
A chance to contribute to the future of mental health research
A clinical research study is now enrolling adults diagnosed with MDD to evaluate whether an investigational medication, taken alongside a standard antidepressant, may improve symptoms of depression.
Participants will continue taking their existing antidepressant and receive either the study medication or a placebo (contains no active ingredients). Those who qualify may receive:
Study medication or placebo in addition to your current treatment
Care and monitoring from a dedicated study team
Reimbursement for time, travel, and study-related expenses
A chance to contribute to the future of mental health research
Are you aged 18 - 65 years with symptoms of OCD for at least one year (even without a formal diagnosis) and taking an anti-depressant that is not fully helping? Obsessive Compulsive Disorder (OCD) is a disorder that can affect men, women, and children, making them experience intrusive thoughts or compulsive behaviours and feel the need to perform specific tasks that become part of their routine repeatedly to relieve the distress caused by the obsession.
If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
Healthy volunteer for an Acute Gastroenteritis (Stomach bug) Clinical Trial
A Study to Evaluate the Efficacy and Safety of a Potential Vaccine Against Acute Gastroenteritis (Stomach bug/Stomach Flu) Caused by Norovirus in Adults ≥18 Years of Age in the United States.
Acute gastroenteritis (Stomach bug/Stomach Flu) is a medical condition characterized by digestive system inflammation, often resulting from a viral or bacterial infection. Common symptoms include diarrhoea, vomiting, and abdominal pain. Treatment usually involves rest, hydration, and, in some cases, medication.
This study aims to assess the effectiveness and safety of a vaccine designed to prevent acute gastroenteritis caused by norovirus in adults aged 18 and older. By participating, you will contribute to important medical research and help in the development of a potential new vaccine for norovirus.
If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
Are you aged 40 - 85 years with a diagnosis of COPD for at least a year and interested in participating in clinical trial studies? If you are a smoker and suffer from mild to moderate chronic obstructive pulmonary disease (COPD), then this trial may be for you.
If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
Are you interested in participating in a Covid-19 Vaccine Booster Clinical Trial Study? Are you an adult, and have taken two primary covid-19 vaccinations and one booster dose? Or a child above 12 years of age and has taken two primary covid-19 vaccinations with or without a booster dose? You may be eligible to participate in the study.
If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
Study for Adults with Obesity or Excess Weight (Overweight)
For participants who are 18 to 75 years old and have a BMI greater than 30 or a BMI greater than 27 with at least one of the following conditions: high blood pressure, high cholesterol, heart disease, or obstructive sleep apnea. Eligible participants should not have had any significant weight changes in the past three months, should not have taken weight loss medications during this period, and should not have undergone or be planning to undergo bariatric surgery or the fitting of a weight loss device. Additionally, individuals with diabetes are not eligible. Participants must also be willing to use approved forms of contraception during the study. Further criteria will be assessed to confirm eligibility.
The study is investigating an investigational drug designed to mimic the effects of amylin, a hormone that signals fullness, delays gastric emptying, and lowers blood sugar levels. By working like amylin, the drug aims to help reduce food intake and promote weight loss. Participants in the study will receive a weekly injection of either the study drug or a placebo for up to 36 weeks (approximately eight months). If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
Recruitment for this study has ended but you can register your interest in future Dermatitis/Eczema trials.
Recruitment for this study has ended but you can register your interest in future Type 2 diabetes trials.
If you are interested in participating in similar studies in the future, please register your interest in similar studies in the future
